Healthcare / BiotechnologyShanghai
$18.78
+0.14 (+0.73%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-79.9M · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.5B
P/E
N/A
•EV/EBITDA
57.4x
↑ROE
-0.4%
↓Gross Margin
69.5%
↑Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-27.2%
FCF CAGR
—
FCF margin
13.5%
FCF / Net income
-11.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.38B · net income $-16.6M · FCF $185.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.38B | $1.38B | $1.38B | $1.29B | $3.57B |
| Net Income | $-16.6M | $-16.6M | $-18.1M | $-71.0M | $594.2M |
| EBITDA | $136.5M | $136.5M | $121.5M | $76.7M | $744.0M |
| EPS | -0.04 | -0.04 | -0.05 | -0.18 | 1.49 |
| Gross Margin | 69.5% | 69.5% | 69.9% | 71.0% | 68.9% |
| Operating Margin | -2.6% | -2.6% | -4.0% | -3.0% | 34.7% |
| Net Margin | -1.2% | -1.2% | -1.3% | -5.5% | 16.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | 0.19 | 0.32 | 0.10 |
| Current Ratio | 3.39 | 3.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $185.8M | $185.8M | $-84.6M | $-79.9M | $-227.7M |
| Returns | |||||
| ROE | -0.4% | -0.4% | -0.5% | -1.8% | 12.9% |
| Valuation | |||||
| P/E | — | — | — | — | 37.68 |
| EV/EBITDA | 57.42 | 57.42 | 67.71 | 146.86 | 28.64 |
| P/B | 2.05 | 2.05 | 2.01 | 2.97 | 4.86 |
| Growth & Yield | |||||
| Revenue Growth | -0.0% | -0.0% | 7.1% | -64.0% | — |
| EPS Growth | 20.0% | 20.0% | 72.2% | -112.1% | — |
| Dividend Yield | 2.6% | 2.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.05 → -0.04
Residual
-12.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.